12 | Cannabinoid Receptors (Cannabinoid Receptor)IBA
01/2022
-
06/2008 |
10 | EndocannabinoidsIBA
12/2023
-
03/2008 |
6 | Proteins (Proteins, Gene)FDA Link
12/2022
-
01/2014 |
6 | Phosphoric Diester Hydrolases (Phosphodiesterases)IBA
01/2022
-
01/2013 |
6 | Biomarkers (Surrogate Marker)IBA
10/2021
-
08/2009 |
6 | LigandsIBA
09/2020
-
04/2007 |
6 | Ethanol (Ethyl Alcohol)IBA
02/2014
-
07/2007 |
6 | hypericinIBA
12/2012
-
12/2003 |
5 | 1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA
03/2024
-
01/2020 |
5 | Radioisotopes (Radionuclides)IBA
04/2021
-
07/2010 |
5 | Purinergic P2X7 ReceptorsIBA
01/2020
-
01/2016 |
5 | Amyloid (Amyloid Fibrils)IBA
01/2020
-
08/2007 |
5 | N,N- diethyl- 2- (2- (4- (2- fluoroethoxy)phenyl)- 5,7- dimethylpyrazolo(1,5- a)pyrimidin- 3- yl)acetamideIBA
10/2019
-
10/2015 |
5 | CannabinoidsIBA
01/2019
-
01/2008 |
5 | CB1 Cannabinoid Receptor (CB1 Receptor)IBA
02/2014
-
02/2010 |
4 | Somatostatin Receptors (Somatostatin Receptor)IBA
03/2023
-
01/2018 |
4 | fosbretabulin (combretastatin A4)IBA
01/2020
-
09/2011 |
4 | salicylhydroxamic acid (SHAM)IBA
11/2012
-
05/2007 |
3 | Octreotide (Sandostatin)FDA LinkGeneric
06/2023
-
01/2020 |
3 | Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
01/2023
-
01/2018 |
3 | Amyloid beta-PeptidesIBA
01/2022
-
03/2009 |
3 | EnzymesIBA
01/2022
-
01/2013 |
3 | Metabotropic Glutamate 5 ReceptorIBA
01/2020
-
12/2015 |
3 | Contrast MediaIBA
01/2020
-
08/2005 |
3 | LipopolysaccharidesIBA
12/2018
-
10/2015 |
3 | Guanosine Monophosphate (5' Guanylic Acid)IBA
12/2017
-
01/2014 |
3 | SolutionsIBA
10/2015
-
03/2006 |
3 | Pentetic Acid (DTPA)FDA LinkGeneric
06/2013
-
11/2007 |
3 | Oxidopamine (6 Hydroxydopamine)IBA
02/2010
-
11/2006 |
2 | plerixaforFDA Link
03/2024
-
10/2021 |
2 | 68Ga-pentixaforIBA
03/2024
-
10/2021 |
2 | 6- amino- 8- ((6- iodo- 1,3- benzodioxol- 5- yl)thio)- N- (1- methylethyl)- 9H-purine-9-propanamineIBA
01/2023
-
01/2019 |
2 | tau Proteins (tau Protein)IBA
01/2023
-
01/2019 |
2 | 7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA
01/2022
-
01/2020 |
2 | Therapeutic UsesIBA
01/2021
-
10/2015 |
2 | Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
01/2021
-
11/2016 |
2 | Gallium-68IBA
01/2020
-
07/2010 |
2 | Levodopa (L Dopa)FDA LinkGeneric
10/2019
-
03/2012 |
2 | Phosphates (Orthophosphate)IBA
07/2018
-
08/2017 |
2 | Dihydrotachysterol (AT 10)IBA
07/2018
-
08/2017 |
2 | Type 5 Cyclic Nucleotide PhosphodiesterasesIBA
12/2017
-
02/2014 |
2 | 2- oxo- 7- methoxy- 8- butyloxy- 1,2- dihydroquinoline- 3- carboxylic acid cyclohexylamideIBA
11/2016
-
08/2013 |
2 | CationsIBA
04/2013
-
01/2013 |
2 | IodineIBA
07/2012
-
09/2011 |
2 | pamoic acidIBA
07/2010
-
11/2007 |
2 | Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
03/2007
-
01/2005 |
1 | CXC ChemokinesIBA
03/2024 |
1 | RadiopharmaceuticalsIBA
08/2023 |
1 | (2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA
01/2023 |
1 | AntigensIBA
01/2023 |
1 | 18F-JK-PSMA-7IBA
01/2023 |
1 | 3-Iodobenzylguanidine (Iobenguane)IBA
01/2023 |
1 | Muscarinic M4 ReceptorIBA
12/2022 |
1 | Dopamine (Intropin)FDA LinkGeneric
01/2022 |
1 | Apolipoproteins E (ApoE)IBA
01/2022 |